Home » Stocks » TG Therapeutics

TG Therapeutics, Inc. (TGTX)

Stock Price: $20.64 USD 0.26 (1.28%)
Updated Aug 14, 2020 9:41 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.61B
Revenue (ttm) 152,000
Net Income (ttm) -205.50M
Shares Out 126.65M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $20.64
Previous Close $20.38
Change ($) 0.26
Change (%) 1.28%
Day's Open 19.05
Day's Range 20.36 - 20.64
Day's Volume 72,336
52-Week Range 4.95 - 24.76

More Stats

Market Cap 2.61B
Enterprise Value 2.38B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 126.65M
Float 93.43M
EPS (basic) -2.05
EPS (diluted) -2.04
FCF / Share -1.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.54M
Short Ratio 9.16
Short % of Float 15.13%
Beta 2.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17,197.60
PB Ratio 12.05
Revenue 152,000
Operating Income -199.91M
Net Income -205.50M
Free Cash Flow -169.76M
Net Cash 237.45M
Net Cash / Share 1.87
Gross Margin 100.00%
Operating Margin -131,521.05%
Profit Margin -135,198.70%
FCF Margin -111,681.58%
ROA -62.29%
ROE -198.14%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$39.50*
(91.38% upside)
Low
23.0
Current: $20.64
High
65.0
Target: 39.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.150.150.150.150.150.150.150.02--
Revenue Growth0%0%0%0%0%-0.25%699.98%---
Gross Profit0.150.150.150.150.150.150.150.02--
Operating Income-169-174-119-78.97-63.18-55.72-22.97-26.90-0.88-2.02
Net Income-173-173-118-78.25-62.95-55.78-20.48-18.07-0.850.62
Shares Outstanding88.3775.4762.0754.7345.6534.0725.4113.111.930.04
Earnings Per Share-1.96-2.30-1.91-1.60-1.38-1.64-0.81-1.38-0.4416.87
Operating Cash Flow-133-129-93.76-61.59-44.69-35.06-10.74-5.19-0.09-1.97
Capital Expenditures-0.13-0.09--0.34-0.04-0.02-0.01---
Free Cash Flow-133-129-93.76-61.93-44.73-35.08-10.74-5.19-0.09-1.97
Cash & Equivalents14270.1485.3045.4777.8179.3540.4916.469.750.48
Total Debt39.19-0.130.070.210.280.743.164.1718.18
Net Cash / Debt10270.1485.1845.4077.6079.0839.7413.305.58-17.71
Assets16383.6297.3854.7811386.7548.1122.0714.5418.64
Liabilities12459.5830.3918.9111.906.658.066.524.9024.00
Book Value38.6224.0466.9935.8710280.1040.0515.559.62-5.36
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name TG Therapeutics, Inc.
Country United States
Employees 134
CEO Michael Sean Weiss

Stock Information

Ticker Symbol TGTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TGTX
IPO Date December 14, 1995

Description

TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.